Ascendis’ Skytrofa (lonapegsomatropin-tcgd) Receives the US FDA’s Approval for Pediatric Growth Hormone Deficiency Published: Aug 27, 2021 | Tags: Ascendis, Skytrofa, lonapegsomatropin-tcgd, US, FDA, Approval, Pediatric Growth Hormone Deficiency Amgen […]readmore
Shots: The MAA is based on the P-III ADAPT trial evaluating the safety and efficacy of efgartigimod vs PBO in a ratio (1:1) in 167 adult patients with gMG for […]readmore
Shots: Halozyme to receive $30M upfront, $160M milestones, $10M per future target nominations and royalties on sales of products. Argenx to get an exclusive license for Halozyme’s ENHANZE technology targeting […]readmore
Shots: The collaboration is focused on development of Larazotide for Alcoholic Liver Diseases (ALD), including severe alcoholic hepatitis Innovate will conduct an investor update on 17 Dec, 2018 for Larazotide, […]readmore
Shots: Cilag (subsidiary of Janssen) to get worldwide commercialization rights for Cusatuzumab, with an option for Argenx to take part in the US activities. Argenx to receive $300M upfront, $200M equity […]readmore
Shots: AbbVie will obtain a worldwide, exclusive license to develop and commercialize ARGX-115-based products Argenx to receive development, regulatory and commercial milestone payments of up to $625M, and has rights […]readmore
Copyright © 2020 Digiqole. All Right Reserved.